New data from OASIS 4 on oral semaglutide 25 mg to reveal insights on cardiometabolic health among adults with obesity or overweight Additional trial ...
New data from OASIS 4 on oral semaglutide 25 mg to reveal insights on cardiometabolic health among adults with obesity or overweight Additional trial insights ...
Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in high-risk adults with type 2 diabetes.Approval of oral semaglutide ...
The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of ...
Rybelsus can now be used as a primary or secondary prevention pill to lower the risk of major adverse cardiovascular events ...
Semaglutide reduces cardiovascular events by 23% and direct heart disease death risk by 26% compared to dulaglutide in older ...
GLP-1 drugs like Ozempic and Wegovy are transforming public health and consumer habits. Here we explore their explosive ...
Researchers have discovered an enzyme, PapB, that can ‘tie off’ therapeutic peptides into stable rings, which could help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results